Medical Access in Poland

Psilocybin and psilocin are treated as Group I-P psychotropic substances. Under the Polish framework, that supports research-only use rather than routine medical prescribing or reimbursement. [1]Polish Act on Counteracting Drug Addiction [2]Polish psychotropic and narcotic substance lists

MDMA remains controlled in Poland and no authorised medical or public reimbursement route was identified. Lawful use should be treated as limited to authorised research. [1]Polish Act on Counteracting Drug Addiction [2]Polish psychotropic and narcotic substance lists [3]URPL clinical-trial registration information

Esketamine is the clearest Polish patient-access route. Spravato is EU-authorised and Polish procurement/reimbursement evidence identifies esketamine as reimbursed under drug programme B.147 for treatment-resistant depression. [1]EMA Spravato EPAR [2]EU public procurement notice for esketamine under B.147 [3]Polish Ministry of Health reimbursement notices

Ketamine is listed separately from Group I-P psychedelics and can be used medically, but Polish psychiatric use for depression remains off-label. Reviewed sources did not show a national public reimbursement route for antidepressant ketamine. [1]Polish psychotropic and narcotic substance lists [2]ClinicalTrials.gov NCT05565352 ketamine registry [3]Medical University of Gdansk ketamine publication

DMT remains controlled in Poland. No authorised routine medical access or reimbursement pathway was identified outside approved research. [1]Polish Act on Counteracting Drug Addiction [2]Polish psychotropic and narcotic substance lists

5-MeO-DMT is not a routine Polish treatment. Poland is relevant through research links, including the GH001 mebufotenin publication with Medical University of Gdansk authorship, but this does not create patient access. [1]Polish psychotropic and narcotic substance lists [2]JAMA Psychiatry GH001 mebufotenin trial [3]PubMed GH001 mebufotenin trial record

No Polish authorised ibogaine treatment, reimbursement route or strong country-specific clinical programme was identified in the reviewed sources. [1]Polish Act on Counteracting Drug Addiction [2]URPL clinical-trial registration information

No Polish authorised medical or reimbursement route for ayahuasca was identified. DMT-related controls and the lack of a specific access pathway mean it should be treated as unavailable outside authorised research. [1]Polish Act on Counteracting Drug Addiction [2]Polish psychotropic and narcotic substance lists

Mescaline remains a controlled psychotropic substance. No authorised medical or reimbursement pathway was identified outside approved research. [1]Polish psychotropic and narcotic substance lists

2C-family substances remain controlled in Poland. No authorised treatment or reimbursement route was identified in the reviewed sources. [1]Polish psychotropic and narcotic substance lists